Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Friedreich's ataxia patients completing core study SNT-III-002 (NCT00537680) and presenting at Week 24 (Visit 5) of that study~* Body weight ≥ 25kg/55 lbs~* Negative urine pregnancy test~* Patients who in the opinion of the investigator are able to comply with the requirements of this study~Exclusion criteria:~* Adverse events during the course of SNT-III-002(NCT00537680)which in the opinion of the investigator are attributable to idebenone and preclude further treatment with idebenone~* Clinically significant abnormalities of clinical hematology or biochemistry including, but not limited to, elevations greater than 2 times the upper limit of normal of AST, ALT or creatinine~* Treatment with coenzyme Q10, vitamin E (if taken at a dose 5 times above the daily requirement) or other sources of idebenone within the past month~* Parallel participation in another clinical drug trial~* Past or present history of abuse of drugs or alcohol~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): high dose Idebenone

Based on this trial design, predict the completion outcome and termination type (if applicable).